A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.

被引：23
|
作者：
Javle, Milind M. [1 ]
Bridgewater, John A. [2 ]
Gbolahan, Olumide B. [3 ]
Jungels, Christiane [4 ]
Cho, May Thet [5 ]
Papadopoulos, Kyriakos P. [6 ]
Thistlethwaite, Fiona C. [7 ,8 ]
Canon, Jean-Luc Re [9 ]
Cheng Lulu [10 ]
Ioannidis, Sonia [10 ]
Gogov, Sven [10 ]
Aung, Naing [11 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] UCL, Inst Canc, London, England
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[5] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA
[6] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[7] Dept Med Oncol, Manchester, Lancs, England
[8] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England
[9] Grand Hop Charleroi, Dept Hematol Oncol, Charleroi, Belgium
[10] Incyte Corp, Wilmington, DE USA
[11] Univ Texas MD Anderson Canc Ctr, Phase Program 1, Dept Invest Canc Therapeut, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.311
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
311
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer
    Mark K. Doherty
    Vincent C. Tam
    Mairéad G. McNamara
    Raymond Jang
    David Hedley
    Eric Chen
    Neesha Dhani
    Patricia Tang
    Hao-Wen Sim
    Grainne M. O’Kane
    Stephanie DeLuca
    Lisa Wang
    Theresa Pedutem
    Jennifer J. Knox
    British Journal of Cancer, 2022, 127 : 1473 - 1478
  • [32] Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer
    Doherty, Mark K.
    Tam, Vincent C.
    McNamara, Mairead G.
    Jang, Raymond
    Hedley, David
    Chen, Eric
    Dhani, Neesha
    Tang, Patricia
    Sim, Hao-Wen
    O'Kane, Grainne M.
    DeLuca, Stephanie
    Wang, Lisa
    Pedutem, Theresa
    Knox, Jennifer J.
    BRITISH JOURNAL OF CANCER, 2022, 127 (08) : 1473 - 1478
  • [33] Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.
    Chang, Amy E.
    Shahda, Safi
    Harris, William Proctor
    Cohen, Stacey
    Coveler, Andrew L.
    O'Neil, Bert H.
    Gadi, Vijayakrishna K.
    Hibbert, Reina
    Lee, Hannah H.
    Younger, Anne
    McCormick, Kinsey Ann
    Pritchard, Colin
    Redman, Mary Weber
    Chiorean, E. Gabriela
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [34] Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
    Koshkin, V. S.
    Barthelemy, P.
    Gravis, G.
    Goodman, O.
    Duran, I.
    Girones Sarrio, R.
    Hwang, C.
    Garcia-Donas, J.
    Morales Barrera, R.
    Zanetta, S.
    Chisamore, M.
    Liu, M.
    Gil, M.
    Tomlinson, G.
    Elsayed, H.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1136 - S1137
  • [35] Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial.
    Belkouz, Ali
    de Vos-Geelen, Judith
    Eskens, Ferry
    Mathot, Ron A. A.
    van Gulik, Thomas
    van Oijen, Martijn G. H.
    Punt, Cornelis J. A.
    Wilmink, Johanna
    Kluempen, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
    Feng, Kaichao
    Liu, Yang
    Zhao, Yongtian
    Yang, Qingming
    Dong, Liang
    Liu, Jiejie
    Li, Xiang
    Zhao, Zhikun
    Mei, Qian
    Han, Weidong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [37] Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study
    Pape, Ulrich-Frank
    Kasper, Stefan
    Meiler, Johannes
    Sinn, Marianne
    Vogel, Arndt
    Mueller, Lothar
    Burkhard, Oswald
    Caca, Karel
    Heeg, Steffen
    Buechner-Steudel, Petra
    Rodriguez-Laval, Victor
    Kuehl, Anja A.
    Arsenic, Ruza
    Jansen, Holger
    Treasure, Peter
    Utku, Nalan
    CANCERS, 2020, 12 (11) : 1 - 16
  • [38] A phase I study of the toll-like receptor 5 (TLR5) agonist, entolimod in patients (pts) with advanced cancers.
    Bakhribah, Hatoon
    Dy, Grace K.
    Ma, Wen Wee
    Zhao, Yujie
    Opyrchal, Mateusz
    Purmal, Andrei
    Gollnick, Sandra
    Brady, William E.
    Fetterly, Gerald J.
    Ngamphaiboon, Nuttapong
    Reungwetwattana, Thanyanan
    Jacob, Sandra M.
    O'Hara, Corrie
    Siedlecki, Francine
    Adjei, Araba
    Burdelya, Lyudmila
    Bespalov, Ivan
    Miller, Langdon L.
    Gudkov, Andrei
    Adjei, Alex A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Biomarker analysis of first-line camrelizumab plus apatinib in patients with advanced biliary tract cancers: Results from a phase II study.
    Rao, Jian-Hua
    Chen, Dong-Sheng
    Song, Yunjie
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16164 - E16164
  • [40] The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
    Wang, Dongxu
    Yang, Xu
    Long, Junyu
    Lin, Jianzhen
    Mao, Jinzhu
    Xie, Fucun
    Wang, Yunchao
    Wang, Yanyu
    Xun, Ziyu
    Bai, Yi
    Yang, Xiaobo
    Guan, Mei
    Pan, Jie
    Seery, Samuel
    Sang, Xinting
    Zhao, Haitao
    FRONTIERS IN ONCOLOGY, 2021, 11
12345